To determine the impact of MΦ orientation and reprogramming on myeloblasts sensitivity to midostaurin (a FLT3 inhibitor used in AML patients [56]), we co-cultured the MLL-AF4 and FLT3-ITD mutated MV-4-11 AML cells with M- vs. GM- (week#1) or M- vs. R-MΦs (week#2). The gene discussed is FLT3; the disease is acute myeloid leukemia.